Currently, research targets related to osteosarcoma treatment mainly include DNA damage repair and cell cycle, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), PI3K/mTOR pathway, avian myelocytomatosis viral oncogene homolog (MYC), among others, and numerous drugs corresponding to these targets have entered clinical trial stages [157]. Here, VEGFA is linked to osteosarcoma.